Joshua Schultz - PAREXEL International President

  President
Mr. Joshua Schultz is Senior Vice PresidentWorldwide Head of PAREXEL Access of the Company. He is responsible for leadership and oversight of all latestage clinical research, access consulting, drug safety and medical communications activities at the Company. From July 2015 to August 2016, he served as Corporationrationrate Vice President and Worldwide Head of PAREXEL Access. From January 2014 to July 2015, he served as Corporationrationrate Vice President and Worldwide Head of PeriPost Approval Clinical Excellence. From July 2009 to January 2014, he served as Corporationrationrate Vice President, Strategic Partnerships. Prior to joining PAREXEL, he served as Vice President of Corporationrationrate Development at Veritas Medicine, a developer of an online compliance system for clinical data disclosure. Previously, he worked at Mercer Management Consulting, where he developed growth strategies for Fortune 500 companies
Age: 41  President Since 2016      
781 487-9900  http://www.parexel.com
Schultz holds a Master of Philosophy degree in International Relations from the University of Cambridge, U.K. He also holds a BS in Economics degree from the Wharton School of Business and a Bachelor of Arts degree in International Relations from the University of Pennsylvania.

Management Efficiency

The company has return on total asset (ROA) of 6.72 % which means that it generated profit of $6.72 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 16.93 % meaning that it created $16.93 on every $100 dollars invested by stockholders.
The company currently holds 671.5M in liabilities with Debt to Equity (D/E) ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Showing few of many executives

PRESIDENT Since

Raghav ChariDr Reddys Laboratories Ltd
2013
Roman TrawickiZoetis
2015
Joyce LeeZoetis
2012
Clinton LewisZoetis
2018
Svend AndersenPerrigo Company plc
2017
Scott JamisonPerrigo Company plc
2011
James MichaudPerrigo Company plc
2016
Samiran DasDr Reddys Laboratories Ltd
2016
Marc CouckePerrigo Company plc
N/A
Ronald JanishPerrigo Company plc
2015
Thomas FarringtonPerrigo Company plc
2015
Marion McCourtRegeneron Pharmaceuticals
2018
Jeffrey NeedhamPerrigo Company plc
2009
Jatin ShahPerrigo Company plc
2005
Saumen ChakrabortyDr Reddys Laboratories Ltd
2018
Sandra BeatyZoetis
2012
Ian SmithVertex Pharmaceuticals Incorpor
2017
Michael StewartPerrigo Company plc
2004
Michael PartridgeVertex Pharmaceuticals Incorpor
N/A
Louis YuPerrigo Company plc
2013
James DillardPerrigo Company plc
2019

Entity Summary

PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corp (PRXL) is traded on NASDAQ in USA and employs 18,600 people.

PAREXEL International Leadership Team

Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

Stock Performance Indicators

Current Sentiment - PRXL

PAREXEL International Investor Sentiment

Most of Macroaxis users are at this time bullish on PAREXEL International Corp. What is your perspective on investing in PAREXEL International Corp? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Currently Active Assets on Macroaxis

GOOG   
Purchased one share of
few hours ago
Traded for 1221.15
UGAZ   
Purchased over 100 shares of
few hours ago
Traded for 19.55
TWTR   
Purchased over 40 shares of
few hours ago
Traded for 43.23
JD   
Purchased over 60 shares of
few hours ago
Traded for 30.83
MDT   
Purchased few shares of
few hours ago
Traded for 111.18
See also Your Equity Center. Please also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Search macroaxis.com